Hardware, Equipment & Parts
Compare Stocks
5 / 10Stock Comparison
CTS vs PLXS vs VICR vs NOVT vs MKSI
Revenue, margins, valuation, and 5-year total return — side by side.
Hardware, Equipment & Parts
Hardware, Equipment & Parts
Hardware, Equipment & Parts
Hardware, Equipment & Parts
CTS vs PLXS vs VICR vs NOVT vs MKSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts |
| Market Cap | $1.71B | $6.98B | $11.79B | $4.86B | $20.25B |
| Revenue (TTM) | $556M | $4.31B | $453M | $981M | $4.07B |
| Net Income (TTM) | $69M | $188M | $119M | $54M | $327M |
| Gross Margin | 38.7% | 10.1% | 57.3% | 44.4% | 45.2% |
| Operating Margin | 15.9% | 5.2% | 18.1% | 11.9% | 14.8% |
| Forward P/E | 24.6x | 33.8x | 94.3x | 38.2x | 30.4x |
| Total Debt | $122M | $175M | $13M | $342M | $4.69B |
| Cash & Equiv. | $82M | $307M | $403M | $381M | $675M |
CTS vs PLXS vs VICR vs NOVT vs MKSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| CTS Corporation (CTS) | 100 | 280.5 | +180.5% |
| Plexus Corp. (PLXS) | 100 | 406.0 | +306.0% |
| Vicor Corporation (VICR) | 100 | 428.6 | +328.6% |
| Novanta Inc. (NOVT) | 100 | 132.7 | +32.7% |
| MKS Inc. (MKSI) | 100 | 284.8 | +184.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CTS vs PLXS vs VICR vs NOVT vs MKSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CTS is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 1 yrs, beta 1.44, yield 0.3%
- Lower volatility, beta 1.44, Low D/E 22.1%, current ratio 2.30x
- PEG 1.58 vs NOVT's 11.61
- Beta 1.44, yield 0.3%, current ratio 2.30x
PLXS lags the leaders in this set but could rank higher in a more targeted comparison.
VICR carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 13.5%, EPS growth 17.6%, 3Y rev CAGR 0.7%
- 27.0% 10Y total return vs PLXS's 5.2%
- 13.5% revenue growth vs PLXS's 1.8%
- 26.2% margin vs PLXS's 4.4%
Among these 5 stocks, NOVT doesn't own a clear edge in any measured category.
MKSI ranks third and is worth considering specifically for dividends.
- 0.3% yield, vs CTS's 0.3%, (3 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.5% revenue growth vs PLXS's 1.8% | |
| Value | Lower P/E (24.6x vs 30.4x) | |
| Quality / Margins | 26.2% margin vs PLXS's 4.4% | |
| Stability / Safety | Beta 1.44 vs VICR's 2.79 | |
| Dividends | 0.3% yield, vs CTS's 0.3%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +5.4% vs NOVT's +14.6% | |
| Efficiency (ROA) | 16.6% ROA vs NOVT's 3.0%, ROIC 8.9% vs 7.4% |
CTS vs PLXS vs VICR vs NOVT vs MKSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CTS vs PLXS vs VICR vs NOVT vs MKSI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VICR leads in 3 of 6 categories
CTS leads 2 • PLXS leads 0 • NOVT leads 0 • MKSI leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
VICR leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PLXS is the larger business by revenue, generating $4.3B annually — 9.5x VICR's $453M. VICR is the more profitable business, keeping 26.2% of every revenue dollar as net income compared to PLXS's 4.4%. On growth, PLXS holds the edge at +18.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $556M | $4.3B | $453M | $981M | $4.1B |
| EBITDAEarnings before interest/tax | $123M | $261M | $103M | $179M | $945M |
| Net IncomeAfter-tax profit | $69M | $188M | $119M | $54M | $327M |
| Free Cash FlowCash after capex | $88M | $76M | $119M | $48M | $401M |
| Gross MarginGross profit ÷ Revenue | +38.7% | +10.1% | +57.3% | +44.4% | +45.2% |
| Operating MarginEBIT ÷ Revenue | +15.9% | +5.2% | +18.1% | +11.9% | +14.8% |
| Net MarginNet income ÷ Revenue | +12.4% | +4.4% | +26.2% | +5.5% | +8.0% |
| FCF MarginFCF ÷ Revenue | +15.8% | +1.8% | +26.3% | +4.9% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.9% | +18.7% | +11.5% | +8.5% | +15.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +34.1% | +29.1% | +3.4% | -2.2% | +53.2% |
Valuation Metrics
CTS leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 27.3x trailing earnings, CTS trades at a 73% valuation discount to VICR's 100.1x P/E. Adjusting for growth (PEG ratio), CTS offers better value at 1.75x vs NOVT's 28.13x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.7B | $7.0B | $11.8B | $4.9B | $20.2B |
| Enterprise ValueMkt cap + debt − cash | $1.8B | $6.9B | $11.4B | $4.8B | $24.3B |
| Trailing P/EPrice ÷ TTM EPS | 27.33x | 41.65x | 100.13x | 92.71x | 68.83x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.63x | 33.84x | 94.31x | 38.25x | 30.36x |
| PEG RatioP/E ÷ EPS growth rate | 1.75x | 4.27x | 2.23x | 28.13x | — |
| EV / EBITDAEnterprise value multiple | 14.68x | 24.46x | 197.81x | 27.00x | 26.70x |
| Price / SalesMarket cap ÷ Revenue | 3.16x | 1.73x | 28.91x | 4.96x | 5.15x |
| Price / BookPrice ÷ Book value/share | 3.23x | 4.95x | 16.50x | 3.81x | 7.49x |
| Price / FCFMarket cap ÷ FCF | 19.82x | 45.36x | 98.86x | 100.38x | 40.74x |
Profitability & Efficiency
VICR leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
VICR delivers a 18.7% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $4 for NOVT. VICR carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to MKSI's 1.73x. On the Piotroski fundamental quality scale (0–9), PLXS scores 9/9 vs NOVT's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.5% | +12.8% | +18.7% | +4.1% | +12.2% |
| ROA (TTM)Return on assets | +8.9% | +5.9% | +16.6% | +3.0% | +3.7% |
| ROICReturn on invested capital | +11.1% | +11.8% | +8.9% | +7.4% | +6.5% |
| ROCEReturn on capital employed | +12.8% | +12.9% | +5.7% | +8.3% | +7.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 9 | 7 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.22x | 0.12x | 0.02x | 0.26x | 1.73x |
| Net DebtTotal debt minus cash | $40M | -$131M | -$390M | -$39M | $4.0B |
| Cash & Equiv.Liquid assets | $82M | $307M | $403M | $381M | $675M |
| Total DebtShort + long-term debt | $122M | $175M | $13M | $342M | $4.7B |
| Interest CoverageEBIT ÷ Interest expense | 18.18x | 19.62x | — | 4.89x | 2.84x |
Total Returns (Dividends Reinvested)
VICR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VICR five years ago would be worth $30,126 today (with dividends reinvested), compared to $10,573 for NOVT. Over the past 12 months, VICR leads with a +535.7% total return vs NOVT's +14.6%. The 3-year compound annual growth rate (CAGR) favors VICR at 82.5% vs NOVT's -5.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +36.6% | +71.3% | +123.6% | +22.6% | +78.8% |
| 1-Year ReturnPast 12 months | +53.2% | +107.2% | +535.7% | +14.6% | +306.1% |
| 3-Year ReturnCumulative with dividends | +44.5% | +201.9% | +507.9% | -15.2% | +266.0% |
| 5-Year ReturnCumulative with dividends | +83.2% | +174.0% | +201.3% | +5.7% | +66.5% |
| 10-Year ReturnCumulative with dividends | +253.2% | +515.8% | +2704.1% | +853.7% | +750.6% |
| CAGR (3Y)Annualised 3-year return | +13.1% | +44.5% | +82.5% | -5.3% | +54.1% |
Risk & Volatility
CTS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CTS is the less volatile stock with a 1.44 beta — it tends to amplify market swings less than VICR's 2.79 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CTS currently trades 98.4% from its 52-week high vs VICR's 88.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 1.65x | 2.79x | 2.02x | 2.64x |
| 52-Week HighHighest price in past year | $60.81 | $275.83 | $293.95 | $149.95 | $326.83 |
| 52-Week LowLowest price in past year | $36.03 | $115.35 | $40.27 | $98.27 | $71.49 |
| % of 52W HighCurrent price vs 52-week peak | +98.4% | +94.5% | +88.9% | +90.9% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 71.0 | 74.2 | 68.2 | 62.6 | 65.3 |
| Avg Volume (50D)Average daily shares traded | 209K | 344K | 864K | 375K | 1.2M |
Analyst Outlook
Evenly matched — CTS and MKSI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CTS as "Hold", PLXS as "Buy", VICR as "Buy", NOVT as "Buy", MKSI as "Buy". Consensus price targets imply 10.1% upside for NOVT (target: $150) vs -9.3% for MKSI (target: $273). For income investors, MKSI offers the higher dividend yield at 0.29% vs CTS's 0.27%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $251.25 | $245.00 | $150.00 | $272.86 |
| # AnalystsCovering analysts | 4 | 18 | 7 | 3 | 29 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | — | — | — | +0.3% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 0 | — | 0 |
| Dividend / ShareAnnual DPS | $0.16 | — | — | — | $0.87 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.3% | +0.9% | +0.3% | +0.8% | +0.2% |
VICR leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CTS leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
CTS vs PLXS vs VICR vs NOVT vs MKSI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CTS or PLXS or VICR or NOVT or MKSI a better buy right now?
For growth investors, Vicor Corporation (VICR) is the stronger pick with 13.
5% revenue growth year-over-year, versus 1. 8% for Plexus Corp. (PLXS). CTS Corporation (CTS) offers the better valuation at 27. 3x trailing P/E (24. 6x forward), making it the more compelling value choice. Analysts rate Plexus Corp. (PLXS) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CTS or PLXS or VICR or NOVT or MKSI?
On trailing P/E, CTS Corporation (CTS) is the cheapest at 27.
3x versus Vicor Corporation at 100. 1x. On forward P/E, CTS Corporation is actually cheaper at 24. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CTS Corporation wins at 1. 58x versus Novanta Inc. 's 11. 61x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — CTS or PLXS or VICR or NOVT or MKSI?
Over the past 5 years, Vicor Corporation (VICR) delivered a total return of +201.
3%, compared to +5. 7% for Novanta Inc. (NOVT). Over 10 years, the gap is even starker: VICR returned +27. 0% versus CTS's +253. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CTS or PLXS or VICR or NOVT or MKSI?
By beta (market sensitivity over 5 years), CTS Corporation (CTS) is the lower-risk stock at 1.
44β versus Vicor Corporation's 2. 79β — meaning VICR is approximately 94% more volatile than CTS relative to the S&P 500. On balance sheet safety, Vicor Corporation (VICR) carries a lower debt/equity ratio of 2% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CTS or PLXS or VICR or NOVT or MKSI?
By revenue growth (latest reported year), Vicor Corporation (VICR) is pulling ahead at 13.
5% versus 1. 8% for Plexus Corp. (PLXS). On earnings-per-share growth, the picture is similar: Vicor Corporation grew EPS 1764% year-over-year, compared to -16. 9% for Novanta Inc.. Over a 3-year CAGR, NOVT leads at 4. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CTS or PLXS or VICR or NOVT or MKSI?
Vicor Corporation (VICR) is the more profitable company, earning 29.
1% net margin versus 4. 3% for Plexus Corp. — meaning it keeps 29. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTS leads at 15. 6% versus 5. 0% for PLXS. At the gross margin level — before operating expenses — VICR leads at 52. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CTS or PLXS or VICR or NOVT or MKSI more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, CTS Corporation (CTS) is the more undervalued stock at a PEG of 1. 58x versus Novanta Inc. 's 11. 61x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, CTS Corporation (CTS) trades at 24. 6x forward P/E versus 94. 3x for Vicor Corporation — 69. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NOVT: 10. 1% to $150. 00.
08Which pays a better dividend — CTS or PLXS or VICR or NOVT or MKSI?
In this comparison, MKSI (0.
3% yield), CTS (0. 3% yield) pay a dividend. PLXS, VICR, NOVT do not pay a meaningful dividend and should not be held primarily for income.
09Is CTS or PLXS or VICR or NOVT or MKSI better for a retirement portfolio?
For long-horizon retirement investors, CTS Corporation (CTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+253.
2% 10Y return). Vicor Corporation (VICR) carries a higher beta of 2. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTS: +253. 2%, VICR: +27. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CTS and PLXS and VICR and NOVT and MKSI?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.